Cell & Gene Therapy Ltd.
Applying the medecine of the future now
"CELL and GENE THERAPY" Ltd (CGT Ltd) operates across various countries with the purpose of developing new genetic drugs and diagnostic systems.
This is accomplished by attracting specialists and by forming international groups focused at achieving results in concrete projects, stages of research or in consortiums with other specialized structures, research teams and companies.
How I Can
We have taken the non-viral vector approach and attempted to improve it’s main weaknesses. Our vector prioritizes safety and contains four innovative properties:
Improved safety of gene therapy due to absence of antibiotic resistance genes
Absence of any virus elements in the construction, ensuring further safety
Smaller length of vector ensuring a more efficient gene delivery
Producibility and constructability on an industrial scale
We are working on an innovative DNA-vaccine against SARS-CoV-2 coronavirus on the base of our own DNA-vectors, encoding immunogenic epitopes of SARS-CoV-2 proteins.
Currently, we have:
Created samples of the DNA-vaccine;
Completed a package of international patent procedures;
Performed the initial in vitro and in vivo studies;
Confirming the efficiency and safety of the DNA-vaccine;
Prepared process flow documentation of industrial production ensuring acceptable pricing characteristics
At this stage, preclinical studies in animals are being prepared to evaluate the pharmacological activity and safety of the DNA vaccine.
Prof. Schioth Helgi Birgir (Sweden)
Chief Research Officer
- Helgi B. Schiöth - Professor in Pharmacology, Head of Unit of Functional Pharmacology Dept. of Neuroscience, Uppsala University Sweden. H-index of 69 (Scopus).
- According to Thomson Reuters 2014, 2015 and 2016 – and Clarivate Analytics 2017, H. Schiöth is one of the most cited researchers and the “world’s most influential scientific minds”. He is in charge of the genetic, molecular biology and pharmacological input for the projects, as well as playing the key role in preclinical development.
Gamolskiy V. (RF, UAE)
Founder & main shareholder
Experience in implementation of investment business since 1988 in non-ferrous and ferrous metallurgy, mining projects, energy, agriculture, etc. In projects for the development of diagnostic test systems and gene therapy drugs - since 2011. Role in the project: strategic coordination of the project